3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis-Reference-Cited by-同舟云学术

3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis

Published:2017 Issue:18 Volume:56 Page:2407-2413
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Araie Hiroaki¹,Sakamaki Ippei¹,Matsuda Yasufumi¹,Tai Katsunori¹,Ikegaya Satoshi¹,Itoh Kazuhiro¹,Kishi Shinji¹,Oiwa Kana¹,Okura Miyuki¹,Tasaki Toshiki¹,Hosono Naoko¹,Ueda Takanori¹,Yamauchi Takahiro¹

Affiliation:

1. Department of Hematology and Oncology, University of Fukui, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/18/56_8291-16/_pdf

Reference31 articles.

1. 1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107: 265-276, 2006.

2. 2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.

3. 3. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23: 4117-4126, 2005.

4. 4. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-391, 2006.

5. 5. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28: 2373-2380, 2010.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study;Journal of Geriatric Oncology;2023-01

2. Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage III-IV diffuse large B-cell lymphoma;PAK J PHARM SCI;2021

3. A Germinal Center-Associated Microenvironmental Signature Reflects Malignant Phenotype and Outcome of DLBCL;Blood Advances;2021-10-12

4. Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy;Current Oncology;2021-03-23